Contact: David Orenstein
Caption: DAD (Disability Assessment for Dementia) scores worsened on average during the 78-week trial, with "bapi" (dotted blue line) showing no improvement over placebo. This data is from the trial with APOE allele carriers.
Credit: Salloway et. al.
Usage Restrictions: with credit
Related news release: Disappointing Alzheimer's trial yields new ideas